Not all sufferers with CLL require therapy. In spite of all recent improvements, the iwCLL however endorses watchful observation for people with asymptomatic disease.86 This recommendation is based on at the least two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Monoc